An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Zymeworks Announces Participation in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will participate in two upcoming investor conferences. Management will engage in one-on-one meetings and fireside chats at the Guggenheim Oncology Conference on February 9, 2022, at 1:00 p.m. ET, and at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 3:40 p.m. ET. Both sessions will be webcast live and available for replay. Zymeworks focuses on developing multifunctional biotherapeutics, including its lead candidate, zanidatamab.
Positive
None.
Negative
None.
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences.
Guggenheim Oncology Conference 2022. Zymeworks will participate virtually in one-on-one meetings and a fireside chat on February 9th at 1:00 p.m. ET.
11th Annual SVB Leerink Global Healthcare Conference. Zymeworks will participate virtually in one-on-one meetings and a fireside chat on February 17th at 3:40 p.m. ET.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.
When is Zymeworks participating in the Guggenheim Oncology Conference?
Zymeworks will participate in the Guggenheim Oncology Conference on February 9, 2022, at 1:00 p.m. ET.
What time is Zymeworks' session at the SVB Leerink Global Healthcare Conference?
Zymeworks' session at the SVB Leerink Global Healthcare Conference is scheduled for February 17, 2022, at 3:40 p.m. ET.
How can I watch the Zymeworks conference presentations?
The presentations by Zymeworks will be webcast live, and recordings will be available on their website.
What is Zymeworks known for?
Zymeworks is known for developing multifunctional biotherapeutics, including zanidatamab, a bispecific antibody for treating HER2-positive solid tumors.
What is the ticker symbol for Zymeworks?
The ticker symbol for Zymeworks is ZYME, listed on the NYSE.
